| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $79.9M | -47.0% |
| SG&A Expense | $38.8M | -14.0% |
| Operating Income | -$122.2M | +37.7% |
| Net Income | -$115.8M | +37.6% |
| EPS (Basic) | -$1.30 | +39.3% |
| EPS (Diluted) | -$1.30 | +39.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $17.8M | -73.3% |
| Short-term Investments | $63.1M | -39.6% |
| Current Assets | $85.6M | -52.4% |
| Total Assets | $96.6M | -60.3% |
| Current Liabilities | $17.8M | -51.4% |
| Total Liabilities | $17.8M | -76.2% |
| Stockholders' Equity | $78.8M | -53.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$93.6M | +19.6% |
| Capital Expenditures | $119K | -79.9% |
| Investing Cash Flow | $44.8M | -52.0% |
| Financing Cash Flow | $177K | -93.0% |
| Free Cash Flow | -$93.7M | +19.9% |